Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More